Document:

(Exhibit 10.22)
                         EXECUTIVE EMPLOYMENT AGREEMENT

      EXECUTIVE  EMPLOYMENT  AGREEMENT,  dated as of  February  15,  2000,  (the
"Agreement") by and between Medix Resources,  Inc., a Colorado  corporation with
its principal  offices  located at Suite 301, 7100 E. Belleview Ave,  Englewood,
Colorado. ("the Company") and Patricia A. Minicucci (the "Executive").

NOW  THEREFORE,  in  consideration  of the  foregoing  premises and mutual
covenants herein contained, the parties hereto agree as follows:

      1.   Employment.  The Company  agrees to employ the Executive and
the  Executive  agrees  to serve  the  Company  as its  Executive  Vice
President, Operations.

      2. Responsibilities and Supervision. The Executive shall devote all of her
business time and attention to the affairs of the Company and its affiliated
companies. The Executive shall be responsible for the overall operations and
administration of the company in each case subject to the general direction,
approval and supervision of the Company's Chief Executive Officer and Board of
Directors, and to the restrictions, limitations and guidelines set forth by the
Board of Directors in resolutions adopted in the minutes of the Board of
Directors meetings, copies of which shall be provided to the Executive from time
to time. In the performance of her duties, the Executive shall maintain an
office at 305 Madison Avenue New York, NY 10165. The terms "affiliate of" a
company or "affiliated company" as used herein means any company directly or
indirectly controlling, controlled by or under common control with the other
company. A presumption of control shall exist for any person owning or
controlling 10% or more of the outstanding voting securities of a company, and
any officer, director or general partner of a company.

      3.  Term  of   Employment.   The   period   of  the   Executive's
employment under this Agreement shall begin on March 8, 2000 and be for a 2-year
period ending March 1, 2002, subject to the termination provisions set forth in
Paragraphs 10, 11, and 12 hereunder.

      4.  Duties. During the period of her employment hereunder and except for
illness, specified vacation periods and reasonable leaves of absence, the
Executive shall devote his best efforts and all her business time, attention and
skill to the business and affairs of the Company and its affiliated companies,
as such business and affairs now exist and as they may be hereinafter changed or
added to, provided, however, that, with approval of the Board of Directors of
the Company, the Executive may serve, on the board of directors of, or hold any
other offices or positions in, companies or organizations which, in such Board's
judgment, will not present any conflict of interest with the Company or any of
its subsidiaries or affiliates or divisions, or materially affect the
performance of Executive's duties pursuant to this Agreement; and further
provided that the outside business is not a "Business Opportunity" of the
Company, as defined herein. A Business Opportunity of the Company shall be a
product, service, investment, venture or other opportunity, which is either:

      (a) Directly related to or within the scope of theexisting business of the
 Company; or

      (b) Within the logical scope of the business of the Company, as such scope
may be expanded or altered from time-to-time by the Board of Directors.

      5. Compensation.   The  Company   shall  pay  to  the  Executive  as
compensation for her services, the base salary of $200,000 per year or such
higher salary as from time-to-time may be approved by the Board of Directors,
payable bi-monthly in accordance with the Company's normal payroll procedures.
The Executive also is eligible to participate in an annual bonus plan, the terms
and provisions of which will be decided by the Board of Directors. As additional
compensation hereunder, upon the execution of this Agreement, the Company will
grant to the Executive 400,000 options to purchase common stock of the Company
under the Company's 1999 Stock Option Plan, at an exercise price of $4.97. Such
options are intended to be classified as incentive stock options for tax
purposes, and shall vest and expire as provided on Exhibit A attached hereto.
Terms of the Stock Option grant will be set forth in a Stock Option Agreement in
the form used pursuant to such Plan.

      6. Expense Reimbursement. The Company will reimburse the Executive for all
reasonable and necessary expenses incurred by him in carrying out his duties
under this Agreement, including entertainment, travel and lodging costs. The
Executive shall present to the Chief Executive Officer each month an itemized
account of such expenses in such form as is required by the Company's accounting
policies.

      7. Medical  Coverage and Other  Employee  Benefits.  The Executive will be
eligible to participate in the Company's current standard benefits package,
which provides health insurance with limited Company payments, long term
disability, limited sick time accrual, paid holidays, 401(k) Plan participation
when eligible and term life insurance at Executive's cost, on the same basis as
other Executives of the Company.

      8. Vacation Time.  The Executive  shall be entitled to take four (4)
weeks paid vacation per calendar year, which, however shall vest at the rate
of one (1) week per full calendar quarter worked hereunder. Such vacation may
not be taken in any greater than consecutive two (2) week increments. Vacation
time not used by the Executive during the calendar year will be forfeited.
Compensation for annual vacation time vested but not taken by Executive shall be
paid to the Executive at the date of termination.

      9.   Obligations of Executive During and After Employment.

     (a) The Executive agrees that during the terms of heremployment  under this
Agreement or while receiving compensation under this Agreement, she will
engage in no other business activities directly or indirectly, which are or
may be competitive with or which might place him in a competing position to
that of the Company, or any affiliated company.

     (b) The  Executive  realizes  that  during  the  course of her  employment,
Executive will have produced and/or have access to confidential business
plans, information, business opportunity records, notebooks, data, formula,
specifications, trade secrets, customer lists, account lists and secret
inventions and processes of the Company and its affiliated companies.
Therefore, during his employment by the Company or by an affiliated company
or while receiving compensation under this Agreement, the Executive agrees
to hold in confidence and not to directly or indirectly disclose or use or
copy or make lists of any such information, except to the extent authorized
by the Chief Executive Officer of the Company in writing. All records,
files, business plans, documents, equipment and the like, or copies
thereof, including copies on Company computers, relating to Company's
business, or the business of an affiliated company, which Executive shall
prepare, or use, or come into contact with, shall remain the sole property
of the Company, or of an affiliated company, and shall not be removed from
the Company's or the affiliated company's premises without the written
consent of the Chief Executive Officer, and shall be promptly returned to
the Company upon termination of employment with the Company and its
affiliated companies. The Executive further agrees that after the term of
his employment, he will not disclose or make use of any proprietary
information owned by the Company or necessary in the operation of the
Company's products or products under development.

     (c) Because of her  employment  by the Company,  Executive  will have
access to trade secrets and confidential information about the Company, its
business plan, its business opportunities, and its expansion plans into other
geographical areas and its methods of doing business. Executive agrees that for
a period of one (1) year after termination of his employment, she will not,
directly or indirectly compete with the Company in a business that is a
"Business Opportunity" of the Company or defined in Section 4 above.

     (d) In the event a court of competent  jurisdiction  finds any provision of
this Section 9 to be so over broad as to be unenforceable, then such
provision shall be reduced in scope by the court, but only to the extent
deemed necessary by the court to render the provision reasonable and
enforceable, it being the Executive's intention to provide the Company with
the broadest protection possible against harmful competition.

     (e) Irreparable harm should be presumed if any provision of
this Section 9 is breached in any way. Damages would be difficult if not
impossible to ascertain, and the faithful observance of all terms of such
Section is an essential condition of employment with the Company. In light of
these considerations, Executive acknowledges that a court of competent
jurisdiction should immediately enjoin any breach of this Agreement by
Executive, upon the Company's request and the Company is released from the
requirement of posting any bond in connection with temporary or interlocutory
injunctive relief, to the extent permitted by law. Nothing herein shall be
construed as prohibiting the Company from pursuing any other remedy available to
the Company for such breach or threatened breach including, but not limited to,
the recovery of damages from the Executive.

      10. Termination by the Company.

      (a) Termination for Cause by the Company. During the first year of the
term of this Agreement, there can be no termination of the Executive by the
Company except for "Termination for Cause" as outlined below:
Notwithstanding anything herein to the contrary, the Company may, without
liability, terminate the Executive's employment hereunder for cause upon
five days written notice, and thereafter the Company's obligations
hereunder shall cease and terminate. Grounds for termination "for cause"
shall be one or more of the following:

       (1) A willful  breach of duty by the  Executive  during the course of
her employment;

       (2) The conviction of the Executive of a felony;

       (3) Habitual  neglect  of  duty  by the  Executive;  The  Executive's
material failure to perform or meet objective and measurable standards
set by the President and Chief Executive Officer and agreed upon by
the Executive in advance.

       (b) Termination Without Cause by the Company.  After the completion of
the initial year of employment hereunder, the Company may terminate employment
of the Executive upon thirty (30) days written notice without cause. In the
event of termination without cause, the Company will pay the Executive six (6)
months salary as compensation. In addition, at least three months prior to the
expiration of this contract, the Company will either notify the Executive in
writing that the contract will not be renewed or will commence good faith
negotiation to enter into a new or modified contract. However, failure to renew
the Executive's contract shall not be deemed to be "termination without cause"
hereunder.

       11.  Termination  by the Executive.  The Executive,  with or without
cause, may terminate this Agreement upon 90 days' written notice to the Company.
In such event, the Executive shall be required to render the services required
under this Agreement during such 90-day period, unless otherwise directed by the
Board of Directors. Executive will be compensated only through the final day of
his employment.

       12. Termination  Upon  Death  of Executive.  In  addition  to any  other,
provision relating to termination, this Agreement shall terminate upon the
Executive's death. Upon Executive's death, the Company shall pay in a lump
sum, within 45 days of the Executive's death, to such person as the
Executive shall have designated to the Company as her beneficiary, or, if
no such person is designated, to the Executive's estate, an amount equal to
all of the Executive's accrued but unpaid base salary, the value on the
Company's books of any vested but unused vacation time and accrued sick
time, and all unpaid expense reimbursements at the time of Executive's
death.

        13.  Lump  Sum  Compensation.  In the  event  of the  occurrence  of a
"Triggering Event," which shall be defined to include

        (i) change in ownership of 50% or more of the outstanding shares of the
 Company, or

        (ii) the merger, consolidation, reorganization or liquidation of the
Company that results in a change in ownership of 50% or more in the
direct or indirect ownership of the Company before the merger,
consolidation, reorganization or liquidation, the Executive shall
receive a lump sum compensation equal to her annual salary and
incentive or bonus payments, if any, as would have been paid to the
Executive during the Company's then current fiscal year (as if the
Executive had been employed for the full fiscal year), within 30 days
of the Triggering Event. All of Executive's granted but unvested
options shall immediately vest upon the occurrence of a Triggering
Event, and all of the shares underlying all the options held by him
shall be registered on a Form S-8 (or any successor form) in a timely
manner (no more than 45 days after such Triggering Event), to be sold
to her by the Company or its successor as unrestricted and freely
tradable shares. If the total amount of the change of control
compensation were to exceed three times the Executive's base salary
(the average annual taxable compensation of the Executive for the five
years preceding the year in which the change of control occurs), the
Company and the Executive may agree to reduce the lump sum
compensation to be received by Executive in order to avoid the
imposition of the golden parachute tax as provided in the Tax Reform
Act of 1984, as amended by the Tax Reform Act of 1986. In the event
the Executive is required to hire counsel to negotiate on his behalf
in connection with his termination or resignation from the Company
upon the occurrence of a Triggering Event, or in order to enforce her
rights and the obligations of the Company as provided in this
Paragraph, the Company shall reimburse to the Executive all reasonable
attorney's fees which may be expended by the Executive in seeking to
enforce the terms hereof. Such reimbursement shall be paid every 30
days after the Executive provides copies of invoices from the
Executive's counsel to the Company.

       14.  Indemnification.  The  Company  shall  indemnify  and hold  harmless
Executive to the fullest extent and in the manner permitted by the provisions of
the Colorado Business Corporation Act, as it may be amended from time to time.
To the extent that any of the Company's officers or directors are covered by or
benefit from one or more director's and officer's liability insurance policies,
the Executive shall also be covered by or benefit from such policy or policies.

      15. Arbitration. Any controversy, dispute or claim arising out of, or
relating to this Agreement and/or its interpretation shall, unless resolved by
agreement of the parties, be settled by binding arbitration in Denver, Colorado
in accordance with the Rules of the American Arbitration Association for
employment disputes then existing. This Agreement to arbitrate shall be
specifically enforceable under the prevailing arbitration laws of the State of
Colorado. The award rendered by the arbitrators shall be final and judgment may
be entered upon the award in any court of the State of Colorado having
jurisdiction of the matter. If any legal proceeding and/or arbitration is
brought to enforce or interpret the terms of this Agreement, each party shall
bear its own attorney's fees, costs, and necessary disbursements in such legal
proceeding and/or arbitration except as otherwise provided herein.

      16.  General Provisions.

      (a) The Executive's rights and obligations under this Agreement shall
not be transferable by assignment or otherwise, nor shall Executive's rights be
subject to encumbrance or to the claims of the Company's creditors. Nothing in
this Agreement shall prevent the consolidation of the Company, with or its
merger into, any other corporation, or the sale by the Company of all or
substantially all of its property or assets. However, the rights of the
Executive hereunder shall be enforceable against any successor to the Company,
and the rights of the Company hereunder shall benefit any successor to the
Company.

       (b) This  Agreement  and the rights of Executive  with respect to the
obligations and benefits of employment recited in this Agreement, constitute the
entire Agreement between the parties hereto in respect of the employment of the
Executive by the Company and supersede any and all other agreements either oral
or in writing between the parties hereto with respect to the employment of the
Executive.

       (c) The provisions of this Agreement  shall be regarded as divisible,
and if any of said provisions or any part thereof are declared invalid or
unenforceable by a court of competent jurisdiction, the validity and
enforceability of the remainder of such provisions or parts thereof and the
applicability thereof shall not be affected thereby.

       (d) This Agreement may not be amended or modified except by a written
instrument executed by Company and Executive.

       (e) This Agreement and the rights and obligations  hereunder shall be
governed by and construed in accordance with the laws of the State of Colorado,
excluding however, the provisions governing conflicts of laws.

        17.  Construction.  Throughout  this  Agreement,  the singular  shall
include the plural, and the plural shall include the singular, and the masculine
and neuter shall include the feminine, wherever the context so requires.

        18. Text to Control.  The  headings of  paragraphs  and  sections are
included solely for convenience of reference. If any conflict between any
heading and the text of this Agreement exists, the text shall control.

        19.  Authority.  The officer  executing  this  Agreement  on behalf
of the Company has been empowered and directed to do so by the Board of
Directors of the Company.

      IN WITNESS  WHEREOF,  the Company and the  Executive  hereby  execute this
Agreement, as of the date first above written, with the full intention to be
mutually bound by the terms hereof.

                              FOR THE COMPANY:
                              MEDIX RESOURCES, INC.

                              By:/s/John R. Prufuta
                              ---------------------
                              John R. Prufeta
                              President and Chief Executive Officer

                              THE EXECUTIVE:

                              By:/s/Patricia Minicucci
                              ------------------------
                              Patricia Minicucci

EXHIBIT A

                          VESTING SCHEDULE FOR OPTIONS

Options covering 400,000 shares of the Company common stock shall be granted to
Executive upon the execution of this Employment Agreement, which shall vest as
follows: options covering 50,000 shares will vest immediately and options
covering 50,000 shares shall vest on the same date of each third month from the
prior vesting date, until all options have vested (which date shall be 21 months
from the date of this Agreement), so long as Executive is still employed by the
Company on each of those vesting dates. However, in order to qualify for the
exemption provided by Rule 16b-3, in no case shall Executive transfer or dispose
of any option (other than by exercise) or the underlying common stock granted
hereunder for a period of six months plus one day from the date of this
Agreement. The expiration date of all of the options granted hereunder shall be
the earlier of five years from the date of this Agreement or 90 days after the
Executive leaves the employment of the Company.10.24

                                                                  EXECUTION COPY
                          AGREEMENT AND PLAN OF MERGER

      This  Agreement  and Plan of Merger is entered into as of March 8, 2000 by
and among Medix Resources, Inc., a Colorado corporation (Medix), Cymedix Lynx
Corporation, a Colorado corporation wholly owned by the Company (Cymedix) and
Automated Design Concepts, Inc., a New Jersey corporation (the ADC), and
joined in by David R. Pfeil (the ADC Shareholder).

      The parties  wish to effect the merger of ADC with and into Cymedix on the
terms and conditions hereof (the Merger). By approving resolutions authorizing
the Merger, Cymedix and ADC wish to adopt this Agreement as a plan of
reorganization within the meaning of Section 368(a) of the Internal Revenue Code
of 1986, as amended (the Code), and the regulations thereunder, and to cause
the Merger to qualify as a reorganization under the provisions of Section
368(a)(1)(A) of the Code.

      Accordingly,  in  consideration of the  representations  and covenants set
forth herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties agree as follows:

      1.The Merger

      1.1 The  Merger.  At the  Effective  Time (as defined in Section 1.2) and
subject to and upon the terms and conditions of this Agreement and the
applicable provisions of the Colorado Business Corporation Act (the Colorado
Act) and the New Jersey Business Corporation Act (the New Jersey Act), ADC
shall be merged with and into Cymedix, the separate corporate existence of ADC
shall cease, and Cymedix shall continue as the surviving company. Cymedix as the
surviving company after the Merger is sometimes referred to herein as the
ASurviving Company.

      1.2 Effective  Time.  Subject to the  provisions of this  Agreement,  the
parties hereto shall cause the Merger to be consummated by filing a Certificate
of Merger in substantially the form attached as Exhibit A-1 (the New Jersey
Certificate of Merger) with the Secretary of the State of the State of New
Jersey in accordance with the relevant provisions of the New Jersey Act and a
Certificate of Merger in substantially the form attached hereto as Exhibit A-2
(the Colorado Certificate of Merger) with the Secretary of State of the State
of Colorado in accordance with the relevant provisions of the Colorado Act. The
time of filing the Colorado Certificate of Merger is referred to herein as the
Effective Time, and the date on which the Effective Time occurs is sometimes
referred to herein as the Effective Date.

      1.3 Closing.  The closing of the Merger (the Closing)  shall take place
at the  offices of Cymedix at a time and date to be  specified  by the  parties,
which shall be as soon as practicable  after the  satisfaction  or waiver of the
conditions  set  forth  in  Articles  6 and 7 or at such  other  time,  date and
location as the parties  hereto agree in writing (the  Closing  Date).  At the
Closing,

      (a)  Cymedix  shall  deliver  to  ADC  the  various  certificates  and
instruments  required  under  Article 7,

      (b) ADC shall  deliver  to Cymedix  the various  certificates  and
instruments  required under Article 6 and

      (c) Cymedix and ADC shall  execute  and file the  Colorado  Certificate
of Merger with the Secretary of State of the State of Colorado and the New
Jersey Certificate of Merger with the Secretary of State of the State of New
Jersey.

      1.4 Effect of the Merger. At the Effective Time, the effect of the Merger
shall be as provided in this  Agreement  and the  applicable  provisions  of the
Colorado Act and the New Jersey Act.

      1.5 Governing  Documents;  Directors and Officers. At the Effective Time,
the Certificate of Incorporation and the Bylaws of Cymedix (the Cymedix
Governing Documents), each as in effect immediately prior to the Effective
Time, shall be the governing documents of the Surviving Company. The directors
and officers of the Surviving Company shall be the directors and officers of
Cymedix in office immediately prior to the Effective Time, to serve until their
respective successors are duly elected or appointed and qualified.

      1.6 Conversion  of ADC Stock.  At the  Effective  Time,  by virtue of the
Merger and without any action on the part of any party, the following shall
occur:

      (a) Conversion. All shares of common stock, no par value, of ADC (the
ADC Stock) issued and outstanding immediately prior to the Effective Time will
be automatically converted into and become the right to receive

      (i) $100,000 in cash (the Merger Cash) and (ii) 60,400 shares (the Merger
Shares) of common stock, $.001 par value, of Medix (Common Stock). The
certificate representing the Merger Shares shall be registered in the name of
the ADC Shareholder and shall bear a legend reflecting the restricted status of
the Merger Shares under the Securities Act of 1933, as amended (the Securities
Act).

      (b) Adjustments to Merger  Consideration.  The Merger Cash and Merger
Shares issuable to the ADC Shareholder on conversion of the ADC Stock
(collectively, the Merger Consideration) shall not be subject to any
adjustment except in the event of any stock split, reverse stock split, stock
dividend (including any dividend or distribution of securities convertible into
Common Stock), recapitalization or other like change without receipt of
consideration with respect to the Common Stock occurring on or after the date
hereof and prior to the Effective Time (a Recapitalization), in which event
the number of Merger Shares shall be adjusted appropriately to reflect the
Recapitalization.

       1.7 Payment  of Merger  Consideration.  On the  Closing  Date,  ADC shall
deliver to Cymedix properly endorsed certificates representing all of the issued
and outstanding shares of ADC Stock, and Medix shall deliver the Merger
Consideration to the ADC Shareholder. The certificates representing the ADC
Stock surrendered at the Closing (together with any treasury stock of ADC) shall
be canceled.

       1.8 Maintenance of Medical Insurance.  Cymedix shall continue to maintain
ADC's existing medical insurance policy for the benefit of the ADC Employees (as
defined in Section 6.3) at all times after the Effective Time until comparable
coverage is obtained for their benefit after December 31, 2000.

       1.9 Taking of Necessary  Action;  Further Action.  At any time after the
Effective Time, if any further action is necessary or desirable to carry out the
purposes of this Agreement and to vest Cymedix with full right, title and
possession to all assets, property, rights, privileges, powers and franchises of
ADC, the officers and directors of ADC and Cymedix are fully authorized in the
name of their respective companies or otherwise to take, and will take, all such
lawful and necessary action, as long as such action is consistent with this
Agreement.

      2. Representations   and   Warrantees   of   ADC   and   the   ADC
Shareholder. ADC and the ADC Shareholder represent and warrant to Cymedix as
follows:

      2.1 Organization.  ADC is a corporation duly organized,  validly existing
and in good standing under the laws of the State of New Jersey and has the
corporate power to own, lease and operate its property and to carry on its
business as now conducted.

      2.2 Capital Structure and Ownership.

      (a) The  authorized  capital  stock of ADC consists of 2,500 shares of
common stock, no par value, of which there are 100 shares issued and outstanding
 on the date hereof. All outstanding shares of ADC Stock are duly authorized,
validly issued, fully paid and non-assessable and are not subject to preemptive
rights created by statute, the Certificate of Incorporation or Bylaws of ADC or
any agreement or document to which ADC is a party or by which it is bound.There
are no outstanding warrants, options, rights, phantom stock rights, agreements,
convertible or exchangeable securities or other instruments or commitments
pursuant to which ADC is or may become obligated to issue, sell, purchase,
return or redeem any shares of its capital stock or other securities or

       (b) that give any person the right  toreceive  any  benefits or rights
similar to any rights enjoyed by or accruing to the holders of shares of ADC
Stock or other interests of ADC. There are no outstanding bonds, debentures,
notes or other indebtedness having the right to vote on any matters on which
shareholders of ADC may vote.

       (c) The ADC  Shareholder  is the lawful  beneficial  owner of the ADC
Stock, all of which is registered in his name on the stock records of ADC. The
ADC Shareholder has good and marketable title to the ADC Shares and has the full
right to transfer title to thereto, free and clear of any liens, claims,
encumbrances, security interests, options, charges and restrictions of any kind.
Other than this Agreement, the ADC Shares are not subject to any agreement,
arrangement, commitment or understanding that could impair Cymedix=s rights
thereto.

       (d) The ADC Shareholder

       (i) is an  Aaccredited  investor,  as  defined  in Rule 501 under the
Securities Act,

       (ii) have  received,  reviewed  and  considered  all information  deemed
relevant in making an informed decision about accepting the Merger Shares as
part of the Merger Consideration,

       (iii) will acquire the Merger Shares for investment and with no present
intention of distributing or reselling them and

       (iv) is aware that the Merger Shares

       (A) will be deemed to be Arestricted securities for purposes of the
Securities Act and

       (B) may not be sold or otherwise transferred in the absence of an
exemption from the registration requirements of the Securities Act and
applicable state securities laws.

       2.3 Authority.  ADC has all  requisite  corporate  power and authority to
enter into this Agreement and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby have been duly authorized by all necessary
corporate action on the part of ADC, subject only to the filing and recording of
the New Jersey Certificate of Merger pursuant to the New Jersey Act and the
Colorado Certificate of Merger pursuant to the Colorado Act. This Agreement has
been duly executed and delivered by ADC and the ADC Shareholder, and assuming
the due authorization, execution and delivery by Medix and Cymedix, constitutes
the valid and binding obligation of ADC and the ADC Shareholder, enforceable in
accordance with its terms.

       2.4 No  Conflict.

       (a) Except as set forth in Schedule 2.4, the execution and  delivery  of
this  Agreement  by ADC do not,  and the  performance  of this Agreement
by ADC will not,

       (i)  conflict with or violate the Certificate of Incorporation or Bylaws
of ADC,

       (ii) subject to compliance with the requirements set forth in Section
 2.4(b)  below,  conflict  with or violate  any law,  rule, regulation,  order,
 judgment or decree applicable to ADC or by which its properties are bound,  or

       (iii) result in any breach of or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, or impair
the rights of ADC or alter the rights or obligations of any third party
under, or give to others any rights of termination, amendment, acceleration
or cancellation of, or result in the creation of a lien or encumbrance
on any of the properties or assets of ADC pursuant to, any note, bond,
mortgage, indenture, contract, agreement, lease, license, permit,
franchise or other instrument or obligation to which ADC is a party or by which
ADC or its properties are bound or affected.

       (b) No consent, approval, order or authorization of, or registration,
declaration or filing with any court, administrative agency or commission or
other governmental or regulatory body or authority or instrumentality
(Governmental Authority) is required by or with respect to ADC in connection
with the execution and delivery of this Agreement or the consummation of the
transactions contemplated, except for the filing of the Colorado Certificate of
Merger with the Secretary of State of Colorado and the New Jersey Certificate of
Merger with the Secretary of State of the State of New Jersey.

        (c) ADC has  heretofore  delivered  to the Company  true and complete
copies of its Certificate of Incorporation and Bylaws, each as amended to date,
and minute books, including its stock certificate ledger and stock transfer
books.

        2.5 Financial  Statements; Undisclosed  Liabilities.

       (a) The  unaudited financial statements of ADC for the year ended
December 31, 1999 heretofore delivered to Cymedix comply as to form in all
material respects with applicable accounting requirements, were prepared in
accordance with generally accepted accounting principles (GAAP) applied on a
consistent basis during the period involved (except as may be indicated in the
notes thereto) and fairly present the financial position of ADC as of the date
thereof and its results of operations for the period then ended.

        (b) ADC does not have any material  liabilities or obligations of any
nature (whether accrued, absolute, contingent, unasserted or otherwise), except

        (i) as disclosed, reflected or fully reserved against in its balance
sheet as of February 25, 2000 (the ADC Balance Sheet) and any notes thereto,

        (ii) for items set forth in Schedule 2.5 and iii) for liabilities and
obligations incurred in the ordinary course of business consistent with past
practice since the date of the ADC Balance Sheet and not in violation of this
Agreement or in excess of $5,000 in the aggregate.

        (c) Except as set forth in Schedule  2.5,

        (i) ADC has filed or caused to be filed in a timely manner (within any
applicable extension periods) all tax returns, reports and forms required to be
filed by the Internal Revenue Code (the Code) or by applicable state, local or
foreign tax laws,

        (ii) all taxes required to be paid by ADC have been timely paid in full
 and all taxes for current periods are adequately provided for, and

        (iii) no tax liens have been filed and no material claims are being
asserted in writing with respect to any taxes. The federal income tax returns
filed by ADC have never been examined by the Internal Revenue Service.

        2.6 Assets.

        (a) ADC has good and valid title to all assets  reflected on
the ADC Balance Sheet, in each case free and clear of all mortgages, liens,
security interests or encumbrances of any kind except as set forth in Schedule
2.6 (the Scheduled Liens).

        (b) All the  material  tangible  personal  property  of ADC has  been
maintained in all material respects in accordance with good commercial
practices. Each item of material tangible personal property of ADC is in all
material respects in good operating condition and repair, ordinary wear and tear
excepted. All leased personal property of ADC is in all material respects in the
condition required by the terms of the applicable lease during the term of the
lease and upon the expiration thereof.

        2.7 Intellectual  Property. Schedule  2.7 sets forth a true and complete
list of all intellectual property and proprietary rights, whether or not subject
to statutory registration or protection (collectively, ADC Intellectual
Property), owned, used, filed by or licensed to ADC. Except as set forth in
Schedule 2.7, ADC owns and has the right to use, execute, reproduce, display,
perform, modify, enhance, distribute, prepare derivative works of and
sublicense, without payment to any other person, all ADC Intellectual Property,
and the consummation of the transactions contemplated hereby will not conflict
with, alter or impair any of those rights. ADC has not granted any options,
licenses or agreements of any kind relating to the ADC Intellectual Property or
the marketing or distribution thereof, except for nonexclusive licenses to end
users in the ordinary course of business or as otherwise indicated in Schedule
2.7. Except as set forth in Schedule 2.7, ADC is not bound by or a party to any
options, licenses or agreements of any kind relating to the ADC Intellectual
Property. Subject to the rights of third parties set forth in Schedule 2.7, all
ADC Intellectual Property is free and clear of any third party claims and all
liens, security interests and encumbrances whatsoever, other than Scheduled
Liens. The conduct of the business of ADC has not violated, conflicted or
infringed and does not violate, conflict with or infringe the intellectual
property rights of any other person. Except as set forth in Schedule 2.7,

      (i) no claims are pending or, to the knowledge of the ADC Shareholder,
threatened, against ADC by any person with respect to the ownership, validity,
enforceability, effectiveness or use of any ADC Intellectual Property and

      (ii) since its inception, ACD has not received any communications alleging
that it has violated any rights relating thereto.

      2.8  Contracts.

      (a)  Except  as set forth in  Schedule 2.8,  ADC is not a party to or
bound by any of the following:

      (i)  employment or consulting  agreement  that has an aggregate future
liability in excess of $5,000 and is not by ADC upon notice of not more than 30
days for a cost of less than $5,000;

      (ii) covenant of Cymedix not to compete or otherwise restricting the
operations of ADC;

      (iii) lease or similar agreement with any person under which

      (A) ADC is lessee of or holds or uses any  machinery,  equipment,  vehicle
or other tangible  personal  property owned by any other person or

      (B) ADC is a lessor or sublessor  of, or makes  available  for use by any
other  person,  any  tangible personal property owned or leased by ADC;

      (iv)

      (A)  continuing   contract  for  the  future   purchase  of
materials,  supplies or equipment,

      (B) management,  service, consulting or other similar type of contract or

      (C) advertising agreement or arrangement;

      (v)material license,  option or other agreement relating in whole
or in part to

      (A) the ADC Intellectual Property,  including any license or other
agreement under which ADC is licensee or licensor thereof, or

      (B) trade secrets, confidential information or other proprietary rights of
 ADC;

      (vi) agreement,  contract or other instrument under which ADC has
borrowed any money from, or issued any note,  bond,  debenture or other evidence
of indebtedness to, any other person;

      (viii)  agreement,  contract or other  instrument under which

      (A) any person has directly or indirectly  guaranteed  indebtedness,
liabilities or obligations   of  ADC  or

      (B)  ADC  has  directly  or   indirectly   guaranteed indebtedness,
liabilities or obligations of any other person;

      (ix) agreement, contract or other instrument under which ADC has,
directly or indirectly, made any advance, loan, extension of credit or capital
contribution to, or other investment in, any other person;

      (x)agreement,   contract  or  other   instrument   providing  for
indemnification of any person with respect to liabilities relating to any
current or former business of ADC; or

      (xi) other  agreement,  contract or other instrument to which ADC
is a party or by or to which it or any of its assets or business is bound or
subject that has an aggregate future liability to any other person in excess of
$5,000 and is not terminable by ADC upon notice of not more than 300 days for a
cost of less than $5,000.

      (b) Except as set forth in Schedule 2.8, all agreements, contracts or
other instruments of ADC listed or required to be listed in the Schedules hereto
(collectively, the AADC Contracts@) are valid, binding and in full force and
effect and are enforceable by ADC in accordance with its terms. Except as set
forth in Schedule 2.8, ADC has performed all material obligations required to be
performed by it to date under the ADC Contracts and it is not in breach or
default in any material respect thereunder (with or without the lapse of time or
the giving of notice, or both) nor has any other party to any of the ADC
Contracts notified ADC of that party=s belief that ADC is or is likely to become
in breach or default in any material respect thereunder or of that party=s
intention to accelerate or modify in a manner adverse to ADC any of its
obligations or rights thereunder and, to the knowledge of the ADC Shareholder,
no other party to any of the ADC Contracts is in breach or default in any
material respect thereunder (with or without the lapse of time or the giving of
notice, or both).

      2.9 Litigation.  Schedule 2.9 sets forth a list of all pending lawsuits or
claims against or affecting ADC or any of its properties,  assets, operations or
business.  Except as set forth in  Schedule  2.9,

     (a) none of the  lawsuits  or claims listed therein would have a material
adverse affect on ADC if determined adversely to ADC,  individually  or in the
aggregate,

     (b) ADC is not a party or subject to or in default under any judgment,
order, injunction or decree of any Governmental  Authority or arbitration
tribunal applicable to it or any of its properties, assets, operations or
business,

     (iii) there is no lawsuit or claim by ADC pending,  or which ADC intends to
 initiate,  against any other person and

     (iv) to the knowledge of the ADC Shareholder,  there is no pending or
threatened investigation of or affecting ADC by any Governmental Authority.

      2.10 Insurance. ADC maintains policies of fire and casualty, liability and
other forms of insurance in amounts, with deductibles and against risks and
losses that are, in its judgment, reasonable for the business and assets of ADC.
The insurance policies maintained by ADC are listed in Schedule 2.10. Except as
set forth in Schedule 2.10, all of the policies listed therein are in full force
and effect, all premiums due and payable thereon have been paid (other than
retroactive or retrospective premium adjustments that are not yet, but may be,
required to be paid with respect to any period ending prior to the Effective
Date under comprehensive general liability and workmen=s compensation insurance
policies), and no notice of cancellation or termination has been received with
respect thereto. The activities and operations of ADC have been conducted in a
manner conforming in all material respects to all applicable provisions of its
insurance policies.

      2.11  Benefit  Plans.

     (a)  Schedule  2.11  sets  forth a list  and  brief description of all
benefit plans maintained by ADC for the benefit of any of its employees.  ADC
has heretofore  delivered to Cymedix true,  complete and correct copies of

     (i) each benefit plan,

     (ii) the most recent annual report on Form 5500 filed with the  Internal
Revenue  Service with respect to each benefit plan (if required),

     (iii) the most recent summary plan description for each benefit plan
for which a summary plan  description is required and

     (iv) each trust agreement, group annuity contract and other financing and
funding  arrangement  relating to any benefit plan.

     (b) Each benefit plan maintained by ADC has been  administered in all
material respects in accordance with its terms and applicable law. There are no
lawsuits, actions, termination proceedings or other proceedings pending or, to
the knowledge of the ADC Shareholder, threatened against or involving any of
ADC's benefit plans and no investigations by any Governmental Authority or other
claims (except claims for benefits payable in the normal operation of the
benefit plans) pending or threatened against or involving any of its benefit
plans.

      2.12 Absence of Changes or Events.  Except as set forth in Schedule  2.12,

     (a) since the date of the ADC Balance  Sheet,  there has not occurred any
event or events or arisen any change of affairs that, individually or
in the aggregate, has had or could have a material adverse effect,

     (b) since the date of the ADC Balance Sheet, the business of ADC has been
conducted in the ordinary course and in substantially the same manner as
previously conducted,

     (c) ADC has made all reasonable efforts consistent with past practices to
adhere to preserve its relationships with customers, suppliers and others with
whom it deals, and

     (d) from the date of the ADC Balance  Sheet,  ADC has not taken any action
that, if taken after the date of this Agreement, would constitute a breach of
any of its covenants set forth herein.

      2.13  Compliance  with  Applicable  Laws.  Except as set forth on Schedule
2.13, ADC is in compliance in all material respects with all applicable
statutes, laws, ordinances, rules, orders and regulations of any Governmental
Authority applicable to its business and operations.

      2.14  Disclosure.  No  representation  or  warranty  of  ADC  or  the  ADC
Shareholder contained in this Agreement, no statement contained in any document,
certificate or Schedule and no data provided in connection with the due
diligence investigation contemplated by Section 6(a) furnished or to be
furnished by or on behalf of ADC to the Cymedix or any of its representatives
pursuant to this Agreement contains or will contain any untrue statement of a
material fact or omits or will omit to state any material fact necessary, in
light of the circumstances under which it was or will be made, in order to make
the statements herein or therein not misleading or necessary to fully and fairly
provide the information required to be provided therein.

      3. Representations  and  Warrantees  of Medix and  Cymedix.  Medix and
Cymedix represent and warrant to ADC as follows:

      3.1 Organization.  Cymedix  is  a  corporation  duly  organized,  validly
existing and in good standing under the laws of the State of Colorado, is (or
shall be prior to the Effective Time) duly qualified to do business and in good
standing as a foreign corporation in the State of New Jersey, and has the power
to own, lease and operate its property and to carry on its business as now
conducted.

      3.2 Authority.

     (a) Each of Medix and  Cymedix has all  requisite  power and  authority  to
enter into this Agreement and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement and the consummation
of the transactions contemplated hereby have been duly authorized by all
necessary action on the part of Medix and Cymedix, subject only to the
filing and recording of the New Jersey Certificate of Merger pursuant to
the New Jersey Act and the Colorado Certificate of Merger pursuant to the
Colorado Act. This Agreement has been duly executed and delivered by Medix
and Cymedix and, assuming the due authorization, execution and delivery of
this Agreement by ADC, constitutes the valid and binding obligation of
Medix and Cymedix, enforceable in accordance with its terms.

      (b) The Merger  Shares  have been duly  authorized  by all  requisite
corporate action of Medix and shall, upon issuance, be validly issued, fully
paid and nonassessable. Upon delivery to the ADC Shareholder of certificates
representing the Merger Shares, they will acquire good and valid title to their
Merger Shares, free and clear of any liens, claims, encumbrances, security
interests, options, charges and restrictions of any kind, other than those
arising from their own acts or omissions. Other than this Agreement, the Merger
Shares are not subject to any agreement, arrangement, commitment or
understanding, including any restriction relating to the voting, dividend rights
or disposition of the Merger Shares. No stock transfer taxes will be due in the
State of Colorado as a result of the issuance of the Merger Shares.

       (c) The Board of  Directors  of Medix has taken (or shall take by the
Effective Time) all action necessary to approve the issuance of the Merger
Shares pursuant to the Merger. No anti-takeover or similar statute or regulation
applies or purports to apply to the transactions contemplated by this Agreement.

       3.3 No  Conflict.

       (a) The  execution  and delivery of this  Agreement by Medix and Cymedix
do not,  and the  performance  of this  Agreement by them will not,

       (i)  conflict  with  or  violate  the  their  respective  certificates of
incorporation  or bylaws,

       (ii) subject to compliance with the  requirements set forth  in  Section
3.3(b) below, conflict with or violate any law, rule, regulation, order,
judgment or decree applicable to them or by which their properties are
bound or affected, or

       (iii) result in any breach of or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, or impair
their respective rights or alter the rights or obligations of any third
party under, or give to others any rights of termination, amendment,
acceleration or cancellation of, or result in the creation of a lien or
encumbrance on any of their properties or assets pursuant to, any note, bond,
mortgage, indenture, contract, agreement, lease, license, permit, franchise
or other instrument or obligation to which either of them is a party or by which
their properties are bound or affected.

       (b) No consent, approval, order or authorization of, or registration,
declaration or filing with any Governmental Authority is required by or with
respect to Medix or Cymedix in connection with the execution and delivery of
this Agreement or the consummation of the transactions contemplated hereby,
except for the filing of the Colorado Certificate of Merger with the Secretary
of State of Colorado and the New Jersey Certificate of Merger with the Secretary
of State of the State of New Jersey.

      4.Indemnities

      4.1 Survival of Representations.  All representations and warranties made
by the  parties  hereunder  shall  survive  the  Effective  Date until the first
anniversary  thereof  (the  Survival  Date).  ADC  shall  have the  continuing
obligation  until the Closing  promptly  to  supplement  or amend the  Schedules
delivered  hereunder with respect to any matter hereafter  arising or discovered
that,  if  existing  or  known at he date of this  Agreement,  would  have  been
required to be set forth or described in the Schedules hereto.

      4.2 ADC  Shareholder  Indemnity.

      (a)  The  ADC  Shareholder  agrees  to indemnify  and hold harmless
Cymedix from and against all losses, liabilities, claims, damages, costs and
expenses, including reasonable attorneys fees (collectively, Losses and
individually, a Loss) that Cymedix may sustain arising out of any breach by
ADC or the ADC Shareholder of any of their representations, warranties or
covenants in this Agreement. Cymedix shall promptly notify the ADC
Shareholder of the existence of any third party claim, demand or other matter
to which the indemnification obligations of the ADC Shareholder would apply.
The ADC Shareholder shall be entitled, at his expense and with counsel
reasonably acceptable to Cymedix, to assume and conduct the defense of the
claim. If the ADC Shareholder does not undertake the defense of the claim, or
if he has a conflict of interest with respect to the claim, Cymedix shall be
entitled to retain separate counsel reasonably acceptable to the ADC
Shareholder, at the expense of the ADC Shareholder, to conduct the defense.

      (b) The ADC  Shareholder  shall continue to defend and shall bear all
Losses associated with a pending litigation captioned Dezine Healthcare
Solutions, Inc. vs. David R. Pfeil d/b/a Arrow Professional Enterprises and
d/b/a Automated Design Concepts (Docket No. C 80-99, Middlesex County, New
Jersey.

       4.3 Cymedix Indemnity.  Cymedix agrees to indemnify and hold harmless the
ADC Shareholder from and against all Losses that the ADC Shareholder may sustain
arising out of any breach by Medix or Cymedix of any of their representations,
warranties or covenants in this Agreement. The ADC Shareholder shall promptly
notify Cymedix of the existence of any third party claim, demand or other matter
to which the indemnification obligations of Cymedix would apply. Cymedix shall
be entitled, at its expense and with counsel reasonably acceptable to the ADC
Shareholder, to assume and conduct the defense of the claim. If Cymedix does not
undertake the defense of the claim, or if it has a conflict of interest with
respect to the claim, the ADC Shareholder shall be entitled to retain separate
counsel reasonably acceptable to the Cymedix, at the expense of Cymedix, to
conduct the defense.

      5.Conduct of Business Pending Closing

      5.1 Conduct of Operations. ADC agrees, from the date of this Agreement to
the Closing, and unless otherwise approved in advance in writing by Cymedix, it
will conduct its business in the ordinary and usual courses of business and
shall maintain its books of account in a manner that fairly and correctly
reflects its income, expenses, assets and liabilities in accordance with GAAP.

      5.2 Preservation of Representations.  Prior to the Closing, ADC shall not
take any  action  that

      (a) if taken on or before  the date  hereof,  would  make untrue any of
the representations  and warranties  contained in Article 2 or

      (b) would interfere with the ability of Medix or Cymedix to perform this
Agreement.

      5.3 Procuring  Approvals.  ADC shall use its best  efforts  to obtain all
licenses, consents or other approvals required to be obtained from any financial
institution or other person in connection with the consummation of the
transactions contemplated by this Agreement.

      6. Conditions to Obligations of Medix and Cymedix.The obligations of Medix
and Cymedix under this Agreement are subject to the following conditions, any of
which may be waived in writing in whole or in part by Cymedix.

      6.1 No Material  Breaches.  There shall not have been any material breach
of the representations, warranties, covenants and agreements of ADC or the ADC
Shareholder contained in this Agreement, and all of their representations and
warranties shall be true as of the Closing Date, except to the extent that they
are expressly stated to be true as of some other time.

      6.2 Compliance  with  Entire  Agreement.  ADC shall  have  performed  and
complied with all agreements and conditions required by this Agreement to be
performed or complied with by it.

      6.3 Employment  Agreements.  The  employees of ADC listed on Schedule 6.3
(the ADC Employees) shall have entered into employment agreements with Cymedix
in form and substance acceptable to Cymedix.

      6.4 Certain  Consents  Obtained.  ADC shall have  obtained  any  required
written consents of any third parties whose consent is required to the
transactions contemplated by this Agreement.

      6.5 Indebtedness. On the Effective Date, the outstanding indebtedness and
accounts payable of ADC, net of accounts receivable, shall not exceed $40,000 in
the aggregate.

      6.6 Further  Assurances.  ADC or the ADC Shareholder shall have delivered
to Cymedix any documents and further assurances that it may reasonably request
to memorialize the transactions contemplated hereby or to confirm the
satisfaction of the conditions set forth in this Article 6.

      7. Conditions to Obligations  of ADC. The  obligations  of ADC under this
Agreement are subject to the following conditions, any of which may be waived in
writing in whole or in part by ADC.

      7.1 No Material  Breaches.  There shall not have been any material breach
of the representations, warranties, covenants and agreements of the Medix and
Cymedix contained in this Agreement, and all of its representations and
warranties shall be true as of the Closing Date, except to the extent that they
are expressly stated to be true as of some other time.

      7.2 Compliance  with  Entire  Agreement.  Medix and  Cymedix  shall  have
performed and complied with all agreements and conditions required by this
Agreement to be performed or complied with by them.

      7.3 Employment  Agreements.  Cymedix  shall have entered into  employment
agreements with the ADC Employees in form and substance acceptable to them.

      7.4 Office  Lease.  Cymedix shall have entered into a two-year  lease for
the office space currently leased by ADC at 72 Brunswick Woods Drive, East
Brunswick, New Jersey 08816 on terms acceptable to the ADC Shareholder.

      7.5 Further   Assurances.   Cymedix  shall  have  delivered  to  the  ADC
Shareholder any documents and further assurances that he may reasonably request
to memorialize the transactions contemplated hereby or to confirm the
satisfaction of the conditions set forth in this Article 7.

      8.Termination

      8.1 Cymedix Termination.  This Agreement may be terminated by Cymedix and
the transactions contemplated hereby abandoned at any time prior to the Closing
if ADC shall have failed to satisfy any of the conditions set forth in Section 6
or any of those conditions shall have become incapable of fulfillment and shall
not have been waived by Cymedix.

      8.2 ADC  Termination.  This  Agreement  may be  terminated by ADC and the
transactions contemplated hereby abandoned at any time prior to the Closing if
Medix or Cymedix shall have failed to satisfy any of the conditions set forth in
Section 7 or any of those conditions shall have become incapable of fulfillment
and shall not have been waived by ADC.

      8.3 Other  Termination  Events.  This Agreement may be terminated and the
transactions contemplated hereby abandoned by Cymedix or ADC if the Closing does
not occur within 30 days of the date hereof, provided that the party seeking
termination pursuant to this Section 8.3 is not in breach in any of its material
representations, warranties, covenants or agreements contained in this
Agreement.

      8.4 Notice of  Termination.  In the event a party seeks to terminate this
Agreement pursuant to this Section 8, it shall give written notice thereof to
the other party, setting forth in reasonable detail the grounds for termination,
whereupon the transactions contemplated by this Agreement shall be terminated
without further action by any party. In the event of termination, this Agreement
shall become void and of no further force or effect, except that each party
shall return all documents and other material received from or on behalf of the
other party in connection with the transactions contemplated hereby, whether so
obtained before or after the execution hereof. All confidential information
received by a party with respect to the business of the other party shall be
held in confidence notwithstanding any termination of this Agreement.

      9. Miscellaneous

      9.1 Benefit.  This Agreement shall be binding upon and shall inure to the
benefit of the parties and their successors and permitted assigns.

      9.2 Entire  Agreement.  This  Agreement,   including  the  Schedules  and
Exhibits, contains the entire agreement and understanding among the parties
hereto with respect to the subject matter hereof and shall not be modified or
affected by any offer, proposal, statement or representation, oral or written,
made by or for any party in connection with the negotiation of the terms hereof.
There are no representations, promises, warranties, covenants, undertakings or
assurances (express or implied) other than those expressly set forth or provided
for herein and in the other documents referred to herein. This Agreement may not
be modified or amended orally, but only by a writing signed by all the parties
hereto.

      9.3 Construction.  Whenever the context requires, the gender of all words
used in this Agreement includes the masculine, feminine and neuter. The headings
and captions in this Agreement and the Schedules are for convenience and
identification only and are in no way intended to define, limit or expand the
scope and intent of this Agreement or any provision hereof.

      9.4 Governing   Law.  This  Agreement  and  all  rights  and  obligations
hereunder shall be governed by, and construed in accordance with, the law of the
State of Colorado applicable to agreements made and to be performed wholly
within that State, without regard to the conflicts of laws principles of that
State.

      9.5 Expenses.  Each party hereto shall pay its own expenses incidental to
the preparation of this Agreement, the carrying out of the provisions of this
Agreement and the consummation of the transactions contemplated hereby.

      9.6 Assignment.  This  Agreement  may  not  be  assigned  by any party
without the prior written consent of the other parties.

      9.7 Notices. All notices,  requests,  consents and demands by the parties
hereunder shall be delivered by hand, by recognized national overnight courier
or by deposit in the United States mail, postage prepaid, by registered or
certified mail, return receipt requested, addressed to the party to be notified
at the addresses set forth below:

      (a) if to the Medix or Cymedix, to:

               Medix Resources, Inc.
               7100 E. Belleview Avenue B Suite 301
               Englewood, CO 80111
               Attention: President

               With a copy to:

               Cymedix Lynx Corporation
               One Broadwalk B Suite 200
               Thousand Oaks, CA 91360
               Attention: Chairman

       (b) if to ADC or the ADC Shareholder, to:

               Automated Design Concepts, Inc.
               72 Brunswick Woods Drive
               East Brunswick, New Jersey 08816
               New York, NY  10118
               Attn: President

        9.8 Non-waivers.  Neither  any  failure nor any delay on the part of any
party to this Agreement in exercising any right, power or privilege hereunder
shall operate as a waiver of any rights of such party, unless such waiver is
made by a writing executed by the party and delivered to the other parties
hereto, nor shall a single or partial exercise of any right preclude any other
or further exercise of any other right, power or privilege accorded to any party
hereto.

        9.9 Counterparts.  This  Agreement  may  be  executed  in  two  or  more
counterparts, each of which shall be deemed to be an original. It shall not be
necessary when making proof of this Agreement to account for more than one
counterpart.

      IN WITNESS WHEREOF, the parties have executed this Agreement as of the day
and year first above written.

                                    MEDIX RESOURCES, INC.

                                    By:___________________________________
                                       John R. Prufeta,
                                       President and Chief Executive Officer

                                    CYMEDIX LYNX CORPORATION

                                    By:___________________________________
                                       John R. Prufeta,
                                       President and  Chief Executive Officer

                                    AUTOMATED DESIGN CONCEPTS, INC.

                                    By:___________________________________
                                       David R. Pfeil,
                                       President

                                    By:-----------------------------------
                                       David R. Pfeil

                                                                     EXHIBIT A-1

                              CERTIFICATE OF MERGER

                                       OF

                         AUTOMATED DESIGN CONCEPTS, INC.

                                      INTO

                            CYMEDIX LYNX CORPORATION
                           (The Surviving Corporation)

To the Department of the Treasury
State of New Jersey

      Pursuant to the provisions of Section  14A:10-7 of the New Jersey Business
Corporation Act, it is hereby certified that:

      1. The names of the merging corporations  are Automated  Design  Concepts,
Inc., a business corporation organized under the laws of the State of New
Jersey, and Cymedix Lynx Corporation, a business corporation organized under the
laws of the State of Colorado.

      2.Annexed  hereto  as  Annex A and  made a part  hereof  is the  Plan  and
Agreement of Merger for merging Automated Design Concepts, Inc. with and into
Cymedix Lynx Corporation (the Plan of Merger), as approved by the board of
directors of each constituent corporation.

      3.The number of shares of capital stock of Automated Design Concepts, Inc.
that were entitled to be voted at the time of approval of the Plan of Merger by
its shareholders is 100 shares, all of which are of one class and all of which
were voted for approval of the Plan of Merger by unanimous written consent dated
March 8, 2000.

      4.The  applicable  provisions of the laws of the  jurisdiction  of Cymedix
Lynx Corporation relating to the merger of Automated Design Concepts, Inc. with
and into Cymedix Lynx Corporation will have been complied with upon compliance
with the filing requirements thereof.

      5.Cymedix  Lynx  Corporation  hereby  agrees  that it may be  served  with
process in the State of New Jersey in any proceeding for the enforcement of any
obligation of Automated Design Concepts, Inc. or any obligation of Cymedix Lynx
Corporation for which it is previously amenable to suit in the State of New
Jersey and in any proceeding for the enforcement of the rights of a dissenting
shareholder of Automated Design Concepts, Inc. against Cymedix Lynx Corporation;
and Cymedix Lynx Corporation hereby irrevocably appoints the Department of the
Treasury of the State of New Jersey as it agent to accept service of process in
any such proceeding and designates the following post office address outside the
State of New Jersey to which the Department of the Treasury of the State of New
Jersey shall mail a copy of the process in such proceeding:

            Cymedix Lynx Corporation
            One Boardwalk B Suite 200
            Thousand Oaks, CA 91360
            Attention: Chairman

      6. Cymedix Lynx Corporation  will continue its existence as the surviving
corporation under its present name pursuant to the laws of its jurisdiction of
organization.

      Executed on this 14th day of March, 2000.

                                       CYMEDIX LYNX CORPORATION

                                       By:___________________________________
                                          John R. Prufeta,
                                          Chairman of the Board

                                       AUTOMATED DESIGN CONCEPTS, INC.

                                       By:___________________________________
                                          David R. Pfeil,
                                          President

                                                                         ANNEX A

                          PLAN AND AGREEMENT OF MERGER
                                       OF
                         AUTOMATED DESIGN CONCEPTS, INC.
                           (a New Jersey corporation)
                                      INTO
                            CYMEDIX LYNX CORPORATION
                            (a Colorado corporation)

      This Plan of Merger (the APlan of Merger@) was adopted on March 8, 2000 by
the board of directors of Automated Design Concepts, Inc., a business
corporation organized under the laws of the State of New Jersey (ADC), and by
the board of directors of Cymedix Lynx Corporation, a business corporation
organized under the laws of the State of Colorado (Cymedix).

      1.Pursuant to the provisions of the New Jersey  Business  Corporation  Act
(the New Jersey Act) and the provisions of the Colorado Business Corporation
Act (the Colorado Act), ADC shall merge (the Merger) with and into Cymedix,
which shall be the surviving corporation of the Merger.

      2.Effective  upon the filing of  certificates of merger in accordance with
the New Jersey Act and the Colorado Act (the Effective Time), the separate
existence of ADC will cease, and Cymedix will be the surviving entity in the
Merger (the Surviving Company) and will continue to be governed by the laws of
the State of Colorado in accordance with the Colorado Act and the provisions of
its certificate of incorporation and bylaws, which shall continue in full force
and effect until amended in the manner prescribed by the Colorado Act.

      3.The  directors  and  officers  of the  Surviving  Company  shall  be the
directors and officers of Cymedix in office immediately prior to the Effective
Time, to serve until their respective successors are duly elected or appointed
and qualified.

      4.At the Effective Time, all of the issued and  outstanding  capital stock
of ADC will be converted into the right to receive,  in the aggregate,

      (a) cash in the amount of One Hundred Thousand Dollars  ($100,000) and

      (ii) 60,400 shares of  common  stock,  $.001  par  value,  of Medix
Resources, Inc., the parent corporation of Cymedix. No other cash, rights or
securities will be issued in the Merger.

      5.From and after the  Effective  Time,

     (a) Cymedix shall possess all the rights, privileges, powers and franchises
of ADC and shall be subject to all the restrictions, disabilities and duties of
ADC,

     (b) all of the rights, privileges, powers and  franchises of ADC, and all
property and debts due to ADC on whatever account shall be vested in Cymedix,

     (c) all property, rights, privileges, powers and franchises of ADC shall be
as  effectually  the property of Cymedix as they were of ADC, and the title to
any real estate vested by deed or otherwise in ADC shall not revert to or be in
any way  impaired by reason of the Merger,  and

     (d) all  rights  of  creditors  and all  liens  upon any  property  of ADC
shall be preserved unimpaired, and all debts, liabilities and duties of ADC
shall attach to Cymedix and may be enforced against it to the same extent as if
those debts, liabilities and duties had been incurred or contracted by Cymedix.

      6.The Merger shall have all the other  effects  provided by the New Jersey
Act and the Colorado Act.

      7.The Plan of Merger  shall be submitted  to the  shareholders  of ADC for
their approval in the manner prescribed by the provisions of the New Jersey Act,
and the Merger shall be authorized in the manner prescribed by the provisions of
the Colorado Act.

      8.ADC and Cymedix  hereby  stipulate  that,  upon  approval of the Plan of
Merger by the shareholders of ADC entitled to vote thereon in the manner
prescribed by the provisions of the New Jersey Act and authorization of the
Merger in the manner prescribed by the provisions of the Colorado Act, they will
cause to be executed and filed any document prescribed by the provisions of the
New Jersey Act and the Colorado Act, and they will cause to be performed all
acts necessary to effectuate the Merger.

      9.The  proper  officers  of ADC  and of  Cymedix  are  hereby  authorized,
empowered and directed to do any and all acts and to make, execute, deliver and
file any and all instruments and documents that shall be necessary or proper to
carry out or effect any of the provisions of the Plan of Merger. Each of the
parties will use all reasonable efforts to obtain any necessary waivers,
consents and approvals, effect all necessary filings and take all actions
necessary or appropriate to consummate the transactions contemplated by the Plan
of Merger.

      10. Notwithstanding the approval of the Plan of Merger by the shareholders
of ADC entitled to vote thereon in the manner prescribed by the provisions of
the New Jersey Act and authorization of the Merger in the manner prescribed by
the provisions of the Colorado Act, the Merger may be abandoned at any time
prior to the effective time in the State of New Jersey in the event that either
party elects to do so.

AS APPROVED,  ADOPTED AND EXECUTED BY EACH OF THE CONSTITUENT  ENTITIES AND EACH
OF THE OTHER PARTIES TO THE MERGER AGREEMENT AS OF MARCH 8, 2000

                                                                     EXHIBIT A-2

                               ARTICLES OF MERGER
                                       OF
                         AUTOMATED DESIGN CONCEPTS, INC.
                                      INTO
                            CYMEDIX LYNX CORPORATION
                           (The Surviving Corporation)

      Pursuant to the provisions of Section  7-111-105 of the Colorado  Business
Corporation Act (the Act),  Cymedix Lynx Corporation,  a Colorado  corporation
incorporated  on October 28, 1997,  the surviving  corporation  (the Surviving
Corporation) in the merger described herein (the Merger),  hereby  represents
as follows:

      1. Plan of Merger. The Plan and  Agreement  of Merger in the form  annexed
hereto as Annex A, summarizing the principal terms of the Agreement and Plan of
Merger entered into as of March 8, 2000 among the Surviving Corporation,
Automated Design Concepts, Inc., a New Jersey corporation (ADC), and David R.
Pfeil, the sole shareholder of ADC (the Plan), has been approved and adopted
by the Surviving Corporation and ADC in accordance with the requirements of the
Act , the requirements of the laws of the State of New Jersey and the
requirements of the Plan.

      2. Shareholder  Approval. The shareholders of ADC were required to approve
the Plan, and the number of votes cast for approval of the Plan by each group
entitled to vote separately on the Merger were sufficient for approval of the
Plan by that voting group. The shareholder of the Surviving Corporation were not
required to approve the Plan pursuant to Section 7-111-103(7) of the Act.

      3. Effective  Date.  The Merger shall take effect upon the filing of these
Articles of Merger with the office of the Secretary of State of the State of
Colorado and a Certificate of Merger relating to the Merger with the Secretary
of State of the State of New Jersey.

Executed on this 14th day of March, 2000

                                       CYMEDIX LYNX CORPORATION

                                       By:___________________________________
                                          John R. Prufeta,
                                          Chairman the Board

                                       AUTOMATED DESIGN CONCEPTS, INC.

                                       By:___________________________________
                                          David R. Pfeil,
                                          President

                                                                         ANNEX A

                          PLAN AND AGREEMENT OF MERGER
                                       OF
                         AUTOMATED DESIGN CONCEPTS, INC.
                           (a New Jersey corporation)
                                      INTO
                            CYMEDIX LYNX CORPORATION
                            (a Colorado corporation)

      This Plan of Merger (the Plan of Merger) was adopted on March 8, 2000 by
the  board  of  directors  of  Automated  Design  Concepts,   Inc.,  a  business
corporation  organized under the laws of the State of New Jersey (ADC), and by
the board of  directors  of Cymedix  Lynx  Corporation,  a business  corporation
organized under the laws of the State of Colorado (Cymedix).

      1. Pursuant to the provisions of the New Jersey  Business  Corporation Act
(the New Jersey Act) and the provisions of the Colorado Business Corporation
Act (the Colorado Act), ADC shall merge (the Merger) with and into Cymedix,
which shall be the surviving corporation of the Merger.

      2. Effective  upon the filing of certificates of merger in accordance with
the New Jersey Act and the Colorado Act (the Effective Time), the separate
existence of ADC will cease, and Cymedix will be the surviving entity in the
Merger (the Surviving Company) and will continue to be governed by the laws of
the State of Colorado in accordance with the Colorado Act and the provisions of
its certificate of incorporation and bylaws, which shall continue in full force
and effect until amended in the manner prescribed by the Colorado Act.

      3.The  directors  and  officers  of the  Surviving  Company  shall  be the
directors and officers of Cymedix in office immediately prior to the Effective
Time, to serve until their respective successors are duly elected or appointed
and qualified.

      4. At the Effective Time, all of the issued and outstanding  capital stock
of ADC will be converted into the right to receive, in the aggregate,

     (a) cash in the amount of One Hundred Thousand Dollars  ($100,000) and

     (ii) 60,400 shares of  common  stock, $.001  par value, of Medix Resources,
Inc., the parent corporation of Cymedix. No other cash, rights or securities
will be issued in the Merger.

      5. From and after the  Effective  Time,

     (a) Cymedix shall possess all the rights, privileges, powers and franchises
of ADC and shall be subject to all the restrictions, disabilities and duties of
ADC,

     (b) all of the rights, privileges, powers and franchises of ADC, and all
property and debts due to ADC on whatever account shall be vested in Cymedix,

     (c) all property, rights, privileges, powers and franchises of ADC shall be
as effectually the property of Cymedix as they were of ADC, and the title to
any real estate vested by deed or otherwise in ADC shall not revert to or be in
any way impaired by reason of the Merger, and

     (d) all rights of creditors and all liens upon any property of ADC shall be
preserved unimpaired, and all debts, liabilities and duties of ADC shall attach
to Cymedix and may be enforced against it to the same extent as if those debts,
liabilities and duties had been incurred or contracted by Cymedix.

     6. The Merger shall have all the other  effects  provided by the New Jersey
Act and the Colorado Act.

     7. The Plan of Merger shall be submitted  to the  shareholders  of ADC for
their approval in the manner prescribed by the provisions of the New Jersey Act,
and the Merger shall be authorized in the manner prescribed by the provisions of
the Colorado Act.

     8. ADC and Cymedix  hereby  stipulate  that,  upon  approval of the Plan of
Merger by the shareholders of ADC entitled to vote thereon in the manner
prescribed by the provisions of the New Jersey Act and authorization of the
Merger in the manner prescribed by the provisions of the Colorado Act, they will
cause to be executed and filed any document prescribed by the provisions of the
New Jersey Act and the Colorado Act, and they will cause to be performed all
acts necessary to effectuate the Merger.

    9.The  proper  officers  of ADC  and of  Cymedix  are  hereby  authorized,
empowered and directed to do any and all acts and to make, execute, deliver and
file any and all instruments and documents that shall be necessary or proper to
carry out or effect any of the provisions of the Plan of Merger. Each of the
parties will use all reasonable efforts to obtain any necessary waivers,
consents and approvals, effect all necessary filings and take all actions
necessary or appropriate to consummate the transactions contemplated by the Plan
of Merger.

    10. Notwithstanding the approval of the Plan of Merger by the shareholders
of ADC entitled to vote thereon in the manner prescribed by the provisions of
the New Jersey Act and authorization of the Merger in the manner prescribed by
the provisions of the Colorado Act, the Merger may be abandoned at any time
prior to the effective time in the State of New Jersey in the event that either
party elects to do so.

AS APPROVED,  ADOPTED AND EXECUTED BY EACH OF THE CONSTITUENT  ENTITIES AND EACH
OF THE OTHER PARTIES TO THE MERGER AGREEMENT AS OF MARCH 8, 2000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}]]